Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes

被引：21
|
作者：
Imprialos, Konstantinos P. [1 ]
Stavropoulos, Konstantinos [1 ]
Doumas, Michael [2 ]
机构：
[1] Aristotle Univ Thessaloniki, Thessaloniki, Greece
[2] George Washington Univ, Washington, DC USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2017年 / 377卷 / 25期
关键词：
D O I：
10.1056/NEJMc1714163
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2502 / 2502
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of once-weekly exenatide after switching from twice-daily exenatide in patients with type 2 diabetes
    Watanabe, Yuusuke
    Saisho, Yoshifumi
    Inaishi, Jun
    Kou, Kinsei
    Yamauchi, Akira
    Kanazawa, Yasuhiko
    Okubo, Yoshiaki
    Tokui, Mikiya
    Imai, Takatoshi
    Murakami, Rie
    Tsuchiya, Tami
    Sasaki, Hironobu
    Masaoka, Tatsuhiro
    Irie, Junichiro
    Meguro, Shu
    Itoh, Hiroshi
    JOURNAL OF DIABETES INVESTIGATION, 2020, 11 (02) : 382 - 388
  • [22] Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
    Inaishi, Jun
    Saisho, Yoshifumi
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2022, 14 : 19 - 26
  • [23] Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes
    Goldman, Jennifer D.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2020, 45 : 61 - 72
  • [24] Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
    Pierre Johansen
    Jonas Håkan-Bloch
    Aiden R. Liu
    Peter G. Bech
    Sofie Persson
    Lawrence A. Leiter
    PharmacoEconomics - Open, 2019, 3 : 537 - 550
  • [25] Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
    Johansen, Pierre
    Hakan-Bloch, Jonas
    Liu, Aiden R.
    Bech, Peter G.
    Persson, Sofie
    Leiter, Lawrence A.
    PHARMACOECONOMICS-OPEN, 2019, 3 (04) : 537 - 550
  • [26] Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes
    Arslanian, Silva A.
    Hannon, Tamara
    Zeitler, Philip
    Chao, Lily C.
    Boucher-Berry, Claudia
    Barrientos-Perez, Margarita
    Bismuth, Elise
    Dib, Sergio
    Cho, Jang Ik
    Cox, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (05): : 433 - 443
  • [27] Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes
    Senoo, Yuki
    Kami, Masahiro
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (16): : 1529 - 1530
  • [28] Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial
    Lingvay, Ildiko
    Benamar, Malik
    Chen, Liming
    Fu, Ariel
    Jodar, Esteban
    Nishida, Tomoyuki
    Riveline, Jean-Pierre
    Yabe, Daisuke
    Zueger, Thomas
    Rea, Rosangela
    DIABETOLOGIA, 2025, : 739 - 751
  • [29] The efficacy and safety of exenatide once weekly in patients with type 2 diabetes
    Heimburger, Sebastian M.
    Bronden, Andreas
    Johansen, Nicklas J.
    Dejgaard, Thomas F.
    Vilsboll, Tina
    Knop, Filip K.
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (05) : 501 - 510
  • [30] Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial
    Mentz, Robert J.
    Bethel, Angelyn
    Merrill, Peter
    Lokhnygina, Yuliya
    Buse, John B.
    Chan, Juliana C.
    Felicio, Joao S.
    Goodman, Shaun G.
    Choi, Jasmine
    Gustavson, Stephanie M.
    Iqbal, Nayyar
    Lopes, Renato D.
    Maggioni, Aldo P.
    Ohman, Peter
    Pagidipati, Neha J.
    Poulter, Neil R.
    Ramachandran, Ambady
    Reicher, Barry
    Holman, Rury R.
    Hernandez, Adrian F.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (19):
12345